This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Psoriasis  • Dermatologic Procedures  • Phototherapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Dermatol. 2005;141:1589-1590.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

More treatments for psoriasis have been introduced during the past 25 years than for all other diseases in dermatology combined. The impact of those treatments on all dermatologic disease has been profound. For example, psoralen–UV-A was introduced for psoriasis but has changed the treatment of cutaneous T-cell lymphoma.¹ Narrowband UV-B was developed for psoriasis but has had a major impact on the treatment of vitiligo.² Acitretin and its precursor etretinate were both approved for psoriasis but have found an important role in skin cancer prevention.³

The precise prevalence of psoriasis varies from study to study, but all surveys report the prevalence as less than 5%, including the current article by Gelfand et al.⁴ How is it that a condition that affects a small percentage of the population has had such a dramatic effect on our specialty? Perhaps it is the chronic nature of psoriasis or the severe manifestations that are . . . [Full Text of this Article]

AUTHOR INFORMATION
Mark G. Lebwohl, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Impact of Obesity and Smoking on Psoriasis Presentation and Management
Mark D. Herron, Michael Hinckley, Matthew S. Hoffman, Jason Papenfuss, Christopher B. Hansen, Kristina P. Callis, and Gerald G. Krueger
Arch Dermatol. 2005;141(12):1527-1534.
ABSTRACT | FULL TEXT  

Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
Joel M. Gelfand, Rachel Weinstein, Steven B. Porter, Andrea L. Neimann, Jesse A. Berlin, and David J. Margolis
Arch Dermatol. 2005;141(12):1537-1541.
ABSTRACT | FULL TEXT  

Targeted UV-B Phototherapy for Plaque-type Psoriasis
Pravit Asawanonda, Akkrawat Chingchai, and Pawinee Torranin
Arch Dermatol. 2005;141(12):1542-1546.
ABSTRACT | FULL TEXT  

Dose-Response and Time-Course Characteristics of UV-A1 Erythema
Paula E. Beattie, Robert S. Dawe, James Ferguson, and Sally H. Ibbotson
Arch Dermatol. 2005;141(12):1549-1555.
ABSTRACT | FULL TEXT  

Soak and Smear: A Standard Technique Revisited
Ari Benjamin Gutman, Albert M. Kligman, Joslyn Sciacca, and William D. James
Arch Dermatol. 2005;141(12):1556-1559.
ABSTRACT | FULL TEXT  

Relationship Between Smoking and the Clinical Severity of Psoriasis
Cristina Fortes, Simona Mastroeni, Karen Leffondré, Francesca Sampogna, Franco Melchi, Eva Mazzotti, Paolo Pasquini, Damiano Abeni, and for the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group
Arch Dermatol. 2005;141(12):1580-1584.
ABSTRACT | FULL TEXT